Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients […]readmore
Tags : Targeted
Shots: Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the […]readmore
Shots: The company has published the preclinical data from its COVID-19 vaccination program, leading to the introduction of T-VIVA-19 as novel targeted protein vaccine If approved, Sorrento will deploy its […]readmore
Shots: Taiho and Astex to receive $50M up front, up to $2.5B milestones based on preclinical, clinical, regulatory and sales plus royalties on sales. Merck (MSD outside the United States […]readmore
Shots: Prometheus to receive up front, $420M as development, regulatory & commercial milestone with royalties on sales of each program and will be responsible for the identification and validation of […]readmore
Shots: Tango to get $50M upfront plus $1.7B as preclinical fees and milestone payments in addition to royalties in response Gilead has option to license WW rights to five targets […]readmore